Clinical Trials Logo

Aggression clinical trials

View clinical trials related to Aggression.

Filter by:

NCT ID: NCT06453070 Completed - Aggression Clinical Trials

Hasan Kalyoncu University

HKU
Start date: November 20, 2022
Phase:
Study type: Observational

Aggression is a serious problem that appears to be common in forensic psychiatric patients. Determining factors related to aggression is important for psychiatric nurses during the treatment, care and rehabilitation of patients. The aim of this study is to determine the relationship between childhood traumas, cognitive distortions and aggression in forensic psychiatry patients. This descriptive study was conducted with 103 male forensic psychiatry patients treated in a high security forensic psychiatry hospital. The data of study were collected Introductory Information Form, Childhood Psychological Traumas Scale (CTQ), Cognitive Distortions Scale (CDS) and Buss-Perry Aggression Scale (BAQ). In this study, 82.5% of forensic psychiatry patients were male, 50.5% were married, 49.5% had secondary education, 53.4% were not working. It was found that patients diagnosed with Schizophrenia Spectrum and Other Psychotic Disordersa and Bipolar Affective Disorders, who were hospitalised more than 5 times, who used alcohol/substances and who had previous experience of forensic events had higher levels of aggression. There was a significant positive correlation between the childhood traumas, cognitive distortions and aggression. The results of this study reveal important results that will contribute to psychiatric nurses caring for forensic psychiatric patients in determining the patients' aggression and affecting factors during the treatment and care process.

NCT ID: NCT06409416 Not yet recruiting - Lung Neoplasms Clinical Trials

Tumor Cell Plasticity and Aggressiveness in Human Non-small Cell Lung Cancer

Start date: July 1, 2024
Phase:
Study type: Observational

Tumor cell plasticity (TCP) is a conubium of processes which lead to re-activation of developmental programs correlating with epithelial-to-mesenchymal transition, and ultimately leading to acquisition of stem cell properties and transdifferentiation potential. Little is known about the molecular mechanisms governing TCP in lung adenocarcinoma (LUAD), i.e. the most frequent lung cancer subtype. The investigators recently identified prognostic 7-miRNAs/10-mRNAs signatures which accurately identified aggressive LUAD among patients with early-stage disease (Stage I). Furthermore, the investigators showed that such tumors show TCP features i.e. mesenchymal and stem-cell traits, high-metastatic potential. Here, the investigators aim to explore by RNAseq and by immunophenotyping at a single-cell level (scRNAseq/AbSeq), the molecular features of aggressive LUAD to unveil the mechanisms triggering TCP. The investigators predict thier results will be relevant for the development of more effective therapeutic protocols for management of aggressive LUAD.

NCT ID: NCT06292988 Not yet recruiting - Clinical trials for Medullary Thyroid Cancer

Predictive Factors for Medullary Thyroid Cancer Aggressiveness

MYELO
Start date: March 1, 2024
Phase:
Study type: Observational

This study is a retrospective study trying to find the predictive factors for medullary thyroid aggressiveness in terms of tumor metastasis and patients' survival.

NCT ID: NCT06275607 Recruiting - Aggression Clinical Trials

Maladaptive Anger Treatment

Start date: February 7, 2024
Phase: N/A
Study type: Interventional

From a psychoevolutionary perspective, anger is a universal emotion that can serve the function of making us aware of wrongdoing and motivating us to undo/correct the wrongdoing. However, it is well recognized in clinical psychology that anger can be maladaptive, often causing distress and impairment in various areas of day-to-day life; untreated maladaptive anger has been found to raise the risk of certain physical health problems e.g., hypertension and coronary heart disease. At the very extreme, rage has been implicated in aggression and violence. Not surprisingly, there has been a widespread quest for anger treatments or what is popularly called "anger management". One treatment approach that has received increasing empirical support is Cognitive Behavioral Affective Therapy (CBAT), which has been applied to patients with chemical dependence and individuals with chronic pain. To extend this programmatic line of research, the proposed research aims to evaluate the efficacy of CBAT in reducing multiple (psychometric and self-monitored) measures of anger within a community sample.

NCT ID: NCT06244368 Recruiting - Clinical trials for Diffuse Large B-cell Lymphoma

GVM±R in Patients With Relapsed or Refractory Aggressive NHL.

Start date: January 17, 2024
Phase: Phase 2
Study type: Interventional

This is a prospective clinical study to evaluate the safety and efficacy of GVM±R in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL).

NCT ID: NCT06230224 Recruiting - Clinical trials for B-Cell Non-Hodgkin Lymphoma (B-NHL)

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

OLYMPIA-4
Start date: February 15, 2024
Phase: Phase 3
Study type: Interventional

The study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on patients with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding to treatment (also known as 'refractory') or has returned (also known as 'relapsed'). The aim of the study is to see how effective the study drug is compared to standard of care (SOC) therapy. The study is looking at several other research questions, including: - What side effects may happen from taking the study drug versus SOC - How much study drug is in your blood at different times - Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) - Comparing the impact from the study drug versus SOC on your quality-of-life and ability to complete routine daily activities

NCT ID: NCT06176638 Not yet recruiting - Depression Clinical Trials

Resettled Refugee Families for Healing

RRF4H
Start date: June 2024
Phase: N/A
Study type: Interventional

The goal of this type I hybrid effectiveness-implementation trial is to test a family strengthening (FS) model delivered through multiple family groups (MFG) combined with a virtual peer mentoring program called TeenAge Health Consultants (Virtual TAHC) aimed at addressing emotional and behavioral problems among youth born in the U.S. to parents resettled as refugees. The specific aims of the study are: Aim 1: To systematically adapt an evidence-based family strengthening (FS) model delivered through multiple family groups (MFG) combined with a peer mentoring program (Virtual TAHC) (Goal 1). Aim 2: To assess preliminary short- and long-term impact of the combination intervention (MFG + Virtual TAHC) on behavioral emotional disorders (aggressive behavior, antisocial behaviors, anxiety, depression, and Posttraumatic Stress Disorder [PTSD]) related to intergenerational trauma among SGRC in the trial (Goal 2). Aim 3: Utilizing mixed methods and applying the Exploration, Preparation, Implementation, Sustainment (EPIS) framework, examine implementation strategies, facilitators, and barriers of the RRF4H intervention (Goal 3). Participants will receive: 1. Family strengthening intervention delivered through multiple family groups (MFG) where children and one of their biological parents will participate in 16 weekly group sessions to discuss common problems and how to address them. 2. The youth in the intervention will participate in a peer mentorship program called TeenAge Health Consultants (TAHC) consisting of 16 weekly virtual sessions where they interact with other youth to learn about important topics including how to deal with conflict, stay out of trouble, deal with stress, avoid drugs and other topics. Researchers will compare the intervention group to a control group that will receive the usual care to see if the intervention group shows improvement in symptoms compared to the usual care group.

NCT ID: NCT06173518 Recruiting - Clinical trials for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

Start date: November 16, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase Ib study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in pediatric patients with relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B ALL) and r/r B cell Non-Hodgkin lymphoma (B NHL)

NCT ID: NCT06158880 Not yet recruiting - Alcohol Drinking Clinical Trials

Alcohol & Men's Sexual Risk Behaviors

Start date: March 2024
Phase: N/A
Study type: Interventional

This project extends the investigators' previous research regarding the intersecting risks of alcohol, sexual risk behavior (SRB), and sexual aggression (SA) in male drinkers who have sex with women by examining the mediating and moderating roles of both intrapersonal and interpersonal emotional factors. While independent streams of research consistently document alcohol's role in SRB and SA, the investigators' work has demonstrated that these behaviors are related, and that alcohol exacerbates their likelihood both independently and synergistically. The researchers' investigations focus on a particular type of SRB: men's resistance to condom use with female partners who want to have protected sex. Condom use resistance (CUR) is common and normative among young male drinkers, with up to 80% of men reporting engaging in CUR. Of particular concern, research demonstrates that up to 42% of men report using coercive CUR tactics such as emotional manipulation, deception, condom sabotage, and force to obtain unprotected sex. Investigators will evaluate hypotheses that distal and proximal emotional and alcohol factors influence in-the-moment SRB/CUR intentions as well as daily alcohol use and SRB/CUR. The investigators will also examine whether the relationships among assessed variables are similar across experimental and naturalistic settings. That is, investigate the extent to which men's responses in the lab parallel their real-world drinking and SRB/CUR behaviors, particularly regarding self and partner emotions, empathy, and interpersonal stress.

NCT ID: NCT06118567 Recruiting - Clinical trials for Intermittent Explosive Disorder

Effect of Nitrous Oxide on Aggression.

Start date: September 6, 2022
Phase: Phase 2
Study type: Interventional

The goal of this experimental medicine clinical trial is to test the hypothesis that nitrous oxide inhalation will result in a change in neurocircuit function in healthy controls and in individuals with impulsive aggressive tendencies. The main question aims to answer are: Does Nitrous Oxide normalize brain circuit function in impulsively aggressive individuals 24 hours after inhalation. Participants will undergo a 60 minute inhalation session with 50% Nitrous Oxide (or room air at another session) and then undergo an fMRI scan 24 hours later. Researchers will compare healthy controls and impulsively aggressive individuals to see if Nitrous Oxide can normalize the function of cortico-limbic circuits in the latter group.